| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues: | ||||||||||
Revenue from Contract with Customer, Excluding Assessed Tax | ||||||||||
4,111 | 30,481 | 42,220 | 35,368 | - | - | - | - | - | - | - |
Revenue under collaborative research and development arrangements | ||||||||||
- | - | - | - | 26,876 | 7,416 | 9,239 | 82 | 156 | - | 125 |
Revenue under collaborative research and development arrangements with affiliated entities | ||||||||||
- | - | - | - | 779 | 479 | 425 | 577 | 411 | 0 | - |
Revenue under collaborative research and development arrangements | ||||||||||
- | - | - | - | - | - | - | - | - | 213 | 4,929 |
Revenue under collaborative research and development arrangements with affiliated entities | ||||||||||
- | - | - | - | - | - | - | - | - | 313 | 18 |
Revenue under collaborative research and development arrangements | ||||||||||
- | - | - | - | 26,876 | - | - | - | - | - | 125 |
Grants and miscellaneous revenue | ||||||||||
- | - | - | - | 12,916 | 2,560 | 3,802 | 3,458 | 9,227 | 5,549 | 4,005 |
Grants and miscellaneous revenue from affiliated entity | ||||||||||
- | - | - | - | 0 | 0 | - | - | - | 67 | - |
Miscellaneous revenue from affiliated entity | ||||||||||
- | - | - | - | - | - | - | - | - | - | 40 |
Total revenues | ||||||||||
- | - | - | - | 40,572 | 10,456 | 13,467 | 4,118 | 9,795 | 6,144 | 9,120 |
Operating expenses: | ||||||||||
Research and development | ||||||||||
88,017 | 95,257 | 98,572 | 88,712 | 57,791 | 34,095 | 21,368 | 17,984 | 20,032 | 13,256 | 9,408 |
General and administrative | ||||||||||
27,203 | 29,315 | 28,290 | 23,892 | 18,063 | 15,857 | 13,643 | 10,778 | 11,988 | 12,108 | 13,669 |
Gain (Loss) on Disposition of Intangible Assets | ||||||||||
0 | 0 | 1,000 | 1,000 | 1,000 | 0 | 2,000 | 1,151 | 587 | 0 | - |
Total operating expenses | ||||||||||
115,220 | 124,573 | 125,862 | 111,604 | 74,855 | 49,952 | 33,011 | 27,612 | 31,433 | 25,364 | 23,077 |
Loss from operations | ||||||||||
-111,108 | -94,091 | -83,642 | -76,235 | -34,283 | -39,495 | -19,544 | -23,493 | -21,638 | -19,220 | -13,957 |
Other income (expense): | ||||||||||
Interest income | ||||||||||
2,605 | 2,264 | 1,836 | - | - | - | - | - | - | - | - |
Interest expense | ||||||||||
7,948 | 0 | 25 | - | - | - | - | - | - | - | - |
Interest and other income, net | ||||||||||
- | - | - | 1,257 | 305 | 331 | 132 | 166 | 34 | 147 | 30 |
Change in fair value of common stock warrants | ||||||||||
0 | 360 | 806 | 127 | 177 | 348 | -45,632 | 1,982 | 8,690 | 2,403 | -1,286 |
Change in fair value of derivative liability | ||||||||||
-1,763 | 0 | 0 | - | - | - | - | - | - | - | - |
Gain (loss) on investment in affiliated entities | ||||||||||
-3,090 | -1,988 | -6,982 | 1,110 | 2,600 | 2,676 | -1,038 | 1,631 | -2,390 | -969 | -9,244 |
Other income (expense), net | ||||||||||
496 | -1,343 | -197 | - | - | - | - | - | - | - | - |
Net loss before income tax benefit/(provision for income tax) | ||||||||||
-120,809 | -94,798 | -88,205 | -73,740 | -31,200 | -36,140 | -66,083 | - | - | - | - |
Income tax benefit/(provision for income taxes) | ||||||||||
-257 | 2,169 | 0 | 0 | -2,097 | 0 | 0 | - | - | - | - |
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | ||||||||||
-120,551 | -96,967 | -88,205 | -73,740 | -29,102 | -36,140 | -66,083 | -19,712 | -15,304 | -17,638 | -24,458 |
Net loss attributable to non-controlling interest | ||||||||||
-1,192 | 0 | 0 | - | 84 | -18 | -55 | -44 | -51 | -24 | -47 |
Net loss attributable to non-controlling interest | ||||||||||
-1,192 | 0 | 0 | - | 84 | - | - | - | - | - | -47 |
Net loss attributable to Inovio Pharmaceuticals, Inc. | ||||||||||
-119,359 | -96,967 | -88,205 | - | -29,187 | -36,121 | -66,028 | -19,668 | -15,252 | -17,613 | -24,411 |
Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders | ||||||||||
Basic and diluted (in dollars per share) | ||||||||||
- | - | - | - | - | - | - | - | -0.12 | -0.17 | -0.33 |
Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders | ||||||||||
Basic ($ per share) | ||||||||||
-1.21 | -1.05 | -1.08 | -1.01 | -0.43 | -0.61 | -1.43 | -0.58 | - | - | - |
Diluted ($ per share) | ||||||||||
-1.21 | -1.05 | -1.09 | -1.01 | -0.44 | -0.64 | -1.43 | -0.58 | - | - | - |
Weighted average number of common shares outstanding | ||||||||||
Weighted average number of common shares outstanding | ||||||||||
Basic (shares) | ||||||||||
98,717 | 92,539 | 81,777 | 73,214 | 68,198 | 59,127 | 46,087 | 34,127 | - | - | - |
Diluted (shares) | ||||||||||
98,717 | 92,539 | 81,918 | 73,214 | 68,365 | 59,408 | 46,087 | 34,127 | - | - | - |
Basic and diluted (in shares) | ||||||||||
- | - | - | - | - | - | - | - | 126,239 | 103,201 | - |
Weighted average number of common shares outstanding - basic and diluted | ||||||||||
- | - | - | - | - | - | - | - | - | - | 74,714 |
Revenue under collaborative research and development arrangements | ||||||||||
Revenue from Contract with Customer, Excluding Assessed Tax | ||||||||||
3,636 | 29,860 | 28,407 | 6,490 | - | - | - | - | - | - | - |
Revenue under collaborative research and development arrangements with affiliated entities | ||||||||||
Revenue from Contract with Customer, Excluding Assessed Tax | ||||||||||
235 | 449 | 765 | 1,400 | - | - | - | - | - | - | - |
Miscellaneous revenue, including from affiliated entities | ||||||||||
Revenue from Contract with Customer, Excluding Assessed Tax | ||||||||||
237 | 171 | 10,474 | 27,136 | - | - | - | - | - | - | - |
Grants and miscellaneous revenue from affiliated entity | ||||||||||
Revenue from Contract with Customer, Excluding Assessed Tax | ||||||||||
1 | 0 | 2,572 | 340 | - | - | - | - | - | - | - |